Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization

Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization

Abstract Background Memantine, drug approved for moderate to severe Alzheimer’s disease, has not shown to be fully effective. In order to solve this issue, polylactic-co-glycolic (PLGA) nanoparticles could be a suitable solution to increase drug’s action on the target site as well as decrease advers...

Full description

Bibliographic Details
Main Authors: Elena Sánchez-López, Miren Ettcheto, Maria Antonia Egea, Marta Espina, Amanda Cano, Ana Cristina Calpena, Antoni Camins, Nuria Carmona, Amélia M. Silva, Eliana B. Souto, Maria Luisa García
Format: Article
Language:English
Published: BioMed Central 2018-03-01
Series:Journal of Nanobiotechnology
Subjects:
Memantine
Nanoparticles
Alzheimer’s disease
Brain targeting
APPswe/PS1dE9 mice
β-Amyloid plaques
Online Access:http://link.springer.com/article/10.1186/s12951-018-0356-z

Internet

http://link.springer.com/article/10.1186/s12951-018-0356-z

Similar Items